Preclinical proof of principle for orally delivered Th17 antagonist miniproteins
Author:
Berger StephanieORCID, Seeger Franziska, Yu Ta-Yi, Aydin Merve, Yang Huilin, Rosenblum Daniel, Guenin-Macé Laure, Glassman Caleb, Arguinchona Lauren, Sniezek Catherine, Blackstone Alyssa, Carter Lauren, Ravichandran Rashmi, Ahlrichs Maggie, Murphy Michael, Pultz Ingrid Swanson, Kang Alex, Bera Asim K., Stewart Lance, Garcia K. Christopher, Naik Shruti, Spangler Jamie B., Beigel Florian, Siebeck Matthias, Gropp Roswitha, Baker David
Reference59 articles.
1. Ustekinumab as induction and maintenance therapy for Crohn’s disease;Feagan;N. Engl. J. Med.,2016 2. Ustekinumab as induction and maintenance therapy for ulcerative colitis;Sands;N. Engl. J. Med.,2019 3. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases;Yang;Aliment. Pharmacol. Ther.,2022 4. Development of antibodies to ustekinumab is associated with loss of response in patients with inflammatory bowel disease;Roblin;J. Clin. Med.,2023 5. Stelara (ustekinumab) [package insert],2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Oral miniproteins treat IBD;Nature Reviews Drug Discovery;2024-07-25
|
|